ALDX
The clock is ticking
Aldeyra Therapeutics is back in the headlines, but not for a shiny new trial update or a surprise approval. Instead, Faruqi & Faruqi is waving the red flag on a securities class action deadline tied to the company’s March 17, 2026 FDA setback.
Why investors care
The complaint is centered on the FDA’s Complete Response Letter for reproxalap, Aldeyra’s dry eye drug candidate. Regulators said the company’s studies didn’t provide enough well-controlled evidence that the drug actually works — which is the kind of sentence biotech investors read once and then stare into the middle distance for a while.
That matters because legal headlines can do two things at once:
- keep the stock under pressure as investors sort through fallout from the FDA decision
- add another layer of uncertainty around a name that was already dealing with a major regulatory miss
What happens next
The reminder is aimed at investors who bought Aldeyra securities between November 3, 2023 and March 16, 2026. The deadline to respond is May 29, 2026, which means the lawsuit clock is now very much in countdown mode.
Big picture: this isn’t the kind of catalyst bulls were hoping for. When a biotech already gets hit with a CRL, the last thing it needs is a legal shadow stretching over the ticker like a rain cloud with a lawyer attached.